Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies

Katherine G. Meilleur, Minal S. Jain, Linda S. Hynan, Ching Yi Shieh, Eunice Kim, Melissa Waite, Michelle McGuire, Courtney Fiorini, Allan M. Glanzman, Marion Main, Kristy Rose, Tina Duong, Roxanna Bendixen, Melody M. Linton, Irene C. Arveson, Carmel Nichols, Kelly Yang, Kenneth H. Fischbeck, Kathryn R. Wagner, Kathryn North & 13 others Ami Mankodi, Christopher Grunseich, Elizabeth J. Hartnett, Michaele Smith, Sandra Donkervoort, Alice Schindler, Angela Kokkinis, Meganne Leach, A. Reghan Foley, James Collins, Francesco Muntoni, Anne Rutkowski, Carsten G. Bönnemann

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Potential therapies are currently under development for two congenital muscular dystrophy (CMD) subtypes: collagen VI-related muscular dystrophy (COL6-RD) and laminin alpha 2-related dystrophy (LAMA2-RD). However, appropriate clinical outcome measures to be used in clinical trials have not been validated in CMDs. We conducted a two-year pilot study to evaluate feasibility, reliability, and validity of various outcome measures, particularly the Motor Function Measure 32, in 33 subjects with COL6-RD and LAMA2-RD. In the first year, outcome measures tested included: Motor Function Measure 32 (MFM32), forced vital capacity (FVC) percent predicted sitting, myometry, goniometry, 10-meter walk, Egen Klassification 2, and PedsQLTM Generic and Neuromuscular Cores. In the second year, we added the North Star Ambulatory Assessment (NSAA), Hammersmith Functional Motor Scale (HFMS), timed functional tests, Measure of Activity Limitations (ACTIVLIM), Quality of Upper Extremity Skills Test (QUEST), and Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue subscale. The MFM32 showed strong inter-rater (0.92) and internal consistency (0.96) reliabilities. Concurrent validity for the MFM32 was supported by large correlations (range 0.623-0.936) with the following: FVC, NSAA, HFMS, timed functional tests, ACTIVLIM, and QUEST. Significant correlations of the MFM32 were also found with select myometry measurements, mainly of the proximal extremities and domains of the PedsQLTM scales focusing on physical health and neuromuscular disease. Goniometry measurements were less reliable. The Motor Function Measure is reliable and valid in the two specific subtypes of CMD evaluated, COL6-RD and LAMA2-RD. The NSAA is useful as a complementary outcome measure in ambulatory individuals. Preliminary concurrent validity of several other clinical outcome measures was also demonstrated for these subtypes.

Original languageEnglish (US)
Pages (from-to)43-54
Number of pages12
JournalNeuromuscular Disorders
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Collagen Type VI
Muscular Dystrophies
Laminin
Outcome Assessment (Health Care)
Vital Capacity
Upper Extremity
Neuromuscular Diseases
Information Systems
Reproducibility of Results
Fatigue
Collagen
Extremities
Clinical Trials
Health
laminin alpha 2

Keywords

  • Clinical outcome measures
  • Collagen VI related muscular dystrophy
  • Laminin alpha 2 related dystrophy
  • Motor function scales
  • Neuromuscular disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)
  • Neurology

Cite this

Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies. / Meilleur, Katherine G.; Jain, Minal S.; Hynan, Linda S.; Shieh, Ching Yi; Kim, Eunice; Waite, Melissa; McGuire, Michelle; Fiorini, Courtney; Glanzman, Allan M.; Main, Marion; Rose, Kristy; Duong, Tina; Bendixen, Roxanna; Linton, Melody M.; Arveson, Irene C.; Nichols, Carmel; Yang, Kelly; Fischbeck, Kenneth H.; Wagner, Kathryn R.; North, Kathryn; Mankodi, Ami; Grunseich, Christopher; Hartnett, Elizabeth J.; Smith, Michaele; Donkervoort, Sandra; Schindler, Alice; Kokkinis, Angela; Leach, Meganne; Foley, A. Reghan; Collins, James; Muntoni, Francesco; Rutkowski, Anne; Bönnemann, Carsten G.

In: Neuromuscular Disorders, Vol. 25, No. 1, 01.01.2015, p. 43-54.

Research output: Contribution to journalArticle

Meilleur, KG, Jain, MS, Hynan, LS, Shieh, CY, Kim, E, Waite, M, McGuire, M, Fiorini, C, Glanzman, AM, Main, M, Rose, K, Duong, T, Bendixen, R, Linton, MM, Arveson, IC, Nichols, C, Yang, K, Fischbeck, KH, Wagner, KR, North, K, Mankodi, A, Grunseich, C, Hartnett, EJ, Smith, M, Donkervoort, S, Schindler, A, Kokkinis, A, Leach, M, Foley, AR, Collins, J, Muntoni, F, Rutkowski, A & Bönnemann, CG 2015, 'Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies', Neuromuscular Disorders, vol. 25, no. 1, pp. 43-54. https://doi.org/10.1016/j.nmd.2014.09.010
Meilleur, Katherine G. ; Jain, Minal S. ; Hynan, Linda S. ; Shieh, Ching Yi ; Kim, Eunice ; Waite, Melissa ; McGuire, Michelle ; Fiorini, Courtney ; Glanzman, Allan M. ; Main, Marion ; Rose, Kristy ; Duong, Tina ; Bendixen, Roxanna ; Linton, Melody M. ; Arveson, Irene C. ; Nichols, Carmel ; Yang, Kelly ; Fischbeck, Kenneth H. ; Wagner, Kathryn R. ; North, Kathryn ; Mankodi, Ami ; Grunseich, Christopher ; Hartnett, Elizabeth J. ; Smith, Michaele ; Donkervoort, Sandra ; Schindler, Alice ; Kokkinis, Angela ; Leach, Meganne ; Foley, A. Reghan ; Collins, James ; Muntoni, Francesco ; Rutkowski, Anne ; Bönnemann, Carsten G. / Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies. In: Neuromuscular Disorders. 2015 ; Vol. 25, No. 1. pp. 43-54.
@article{7fa6a40106724ef1866258d77ea7b5cf,
title = "Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies",
abstract = "Potential therapies are currently under development for two congenital muscular dystrophy (CMD) subtypes: collagen VI-related muscular dystrophy (COL6-RD) and laminin alpha 2-related dystrophy (LAMA2-RD). However, appropriate clinical outcome measures to be used in clinical trials have not been validated in CMDs. We conducted a two-year pilot study to evaluate feasibility, reliability, and validity of various outcome measures, particularly the Motor Function Measure 32, in 33 subjects with COL6-RD and LAMA2-RD. In the first year, outcome measures tested included: Motor Function Measure 32 (MFM32), forced vital capacity (FVC) percent predicted sitting, myometry, goniometry, 10-meter walk, Egen Klassification 2, and PedsQLTM Generic and Neuromuscular Cores. In the second year, we added the North Star Ambulatory Assessment (NSAA), Hammersmith Functional Motor Scale (HFMS), timed functional tests, Measure of Activity Limitations (ACTIVLIM), Quality of Upper Extremity Skills Test (QUEST), and Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue subscale. The MFM32 showed strong inter-rater (0.92) and internal consistency (0.96) reliabilities. Concurrent validity for the MFM32 was supported by large correlations (range 0.623-0.936) with the following: FVC, NSAA, HFMS, timed functional tests, ACTIVLIM, and QUEST. Significant correlations of the MFM32 were also found with select myometry measurements, mainly of the proximal extremities and domains of the PedsQLTM scales focusing on physical health and neuromuscular disease. Goniometry measurements were less reliable. The Motor Function Measure is reliable and valid in the two specific subtypes of CMD evaluated, COL6-RD and LAMA2-RD. The NSAA is useful as a complementary outcome measure in ambulatory individuals. Preliminary concurrent validity of several other clinical outcome measures was also demonstrated for these subtypes.",
keywords = "Clinical outcome measures, Collagen VI related muscular dystrophy, Laminin alpha 2 related dystrophy, Motor function scales, Neuromuscular disease",
author = "Meilleur, {Katherine G.} and Jain, {Minal S.} and Hynan, {Linda S.} and Shieh, {Ching Yi} and Eunice Kim and Melissa Waite and Michelle McGuire and Courtney Fiorini and Glanzman, {Allan M.} and Marion Main and Kristy Rose and Tina Duong and Roxanna Bendixen and Linton, {Melody M.} and Arveson, {Irene C.} and Carmel Nichols and Kelly Yang and Fischbeck, {Kenneth H.} and Wagner, {Kathryn R.} and Kathryn North and Ami Mankodi and Christopher Grunseich and Hartnett, {Elizabeth J.} and Michaele Smith and Sandra Donkervoort and Alice Schindler and Angela Kokkinis and Meganne Leach and Foley, {A. Reghan} and James Collins and Francesco Muntoni and Anne Rutkowski and B{\"o}nnemann, {Carsten G.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.nmd.2014.09.010",
language = "English (US)",
volume = "25",
pages = "43--54",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies

AU - Meilleur, Katherine G.

AU - Jain, Minal S.

AU - Hynan, Linda S.

AU - Shieh, Ching Yi

AU - Kim, Eunice

AU - Waite, Melissa

AU - McGuire, Michelle

AU - Fiorini, Courtney

AU - Glanzman, Allan M.

AU - Main, Marion

AU - Rose, Kristy

AU - Duong, Tina

AU - Bendixen, Roxanna

AU - Linton, Melody M.

AU - Arveson, Irene C.

AU - Nichols, Carmel

AU - Yang, Kelly

AU - Fischbeck, Kenneth H.

AU - Wagner, Kathryn R.

AU - North, Kathryn

AU - Mankodi, Ami

AU - Grunseich, Christopher

AU - Hartnett, Elizabeth J.

AU - Smith, Michaele

AU - Donkervoort, Sandra

AU - Schindler, Alice

AU - Kokkinis, Angela

AU - Leach, Meganne

AU - Foley, A. Reghan

AU - Collins, James

AU - Muntoni, Francesco

AU - Rutkowski, Anne

AU - Bönnemann, Carsten G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Potential therapies are currently under development for two congenital muscular dystrophy (CMD) subtypes: collagen VI-related muscular dystrophy (COL6-RD) and laminin alpha 2-related dystrophy (LAMA2-RD). However, appropriate clinical outcome measures to be used in clinical trials have not been validated in CMDs. We conducted a two-year pilot study to evaluate feasibility, reliability, and validity of various outcome measures, particularly the Motor Function Measure 32, in 33 subjects with COL6-RD and LAMA2-RD. In the first year, outcome measures tested included: Motor Function Measure 32 (MFM32), forced vital capacity (FVC) percent predicted sitting, myometry, goniometry, 10-meter walk, Egen Klassification 2, and PedsQLTM Generic and Neuromuscular Cores. In the second year, we added the North Star Ambulatory Assessment (NSAA), Hammersmith Functional Motor Scale (HFMS), timed functional tests, Measure of Activity Limitations (ACTIVLIM), Quality of Upper Extremity Skills Test (QUEST), and Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue subscale. The MFM32 showed strong inter-rater (0.92) and internal consistency (0.96) reliabilities. Concurrent validity for the MFM32 was supported by large correlations (range 0.623-0.936) with the following: FVC, NSAA, HFMS, timed functional tests, ACTIVLIM, and QUEST. Significant correlations of the MFM32 were also found with select myometry measurements, mainly of the proximal extremities and domains of the PedsQLTM scales focusing on physical health and neuromuscular disease. Goniometry measurements were less reliable. The Motor Function Measure is reliable and valid in the two specific subtypes of CMD evaluated, COL6-RD and LAMA2-RD. The NSAA is useful as a complementary outcome measure in ambulatory individuals. Preliminary concurrent validity of several other clinical outcome measures was also demonstrated for these subtypes.

AB - Potential therapies are currently under development for two congenital muscular dystrophy (CMD) subtypes: collagen VI-related muscular dystrophy (COL6-RD) and laminin alpha 2-related dystrophy (LAMA2-RD). However, appropriate clinical outcome measures to be used in clinical trials have not been validated in CMDs. We conducted a two-year pilot study to evaluate feasibility, reliability, and validity of various outcome measures, particularly the Motor Function Measure 32, in 33 subjects with COL6-RD and LAMA2-RD. In the first year, outcome measures tested included: Motor Function Measure 32 (MFM32), forced vital capacity (FVC) percent predicted sitting, myometry, goniometry, 10-meter walk, Egen Klassification 2, and PedsQLTM Generic and Neuromuscular Cores. In the second year, we added the North Star Ambulatory Assessment (NSAA), Hammersmith Functional Motor Scale (HFMS), timed functional tests, Measure of Activity Limitations (ACTIVLIM), Quality of Upper Extremity Skills Test (QUEST), and Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue subscale. The MFM32 showed strong inter-rater (0.92) and internal consistency (0.96) reliabilities. Concurrent validity for the MFM32 was supported by large correlations (range 0.623-0.936) with the following: FVC, NSAA, HFMS, timed functional tests, ACTIVLIM, and QUEST. Significant correlations of the MFM32 were also found with select myometry measurements, mainly of the proximal extremities and domains of the PedsQLTM scales focusing on physical health and neuromuscular disease. Goniometry measurements were less reliable. The Motor Function Measure is reliable and valid in the two specific subtypes of CMD evaluated, COL6-RD and LAMA2-RD. The NSAA is useful as a complementary outcome measure in ambulatory individuals. Preliminary concurrent validity of several other clinical outcome measures was also demonstrated for these subtypes.

KW - Clinical outcome measures

KW - Collagen VI related muscular dystrophy

KW - Laminin alpha 2 related dystrophy

KW - Motor function scales

KW - Neuromuscular disease

UR - http://www.scopus.com/inward/record.url?scp=84919870981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919870981&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2014.09.010

DO - 10.1016/j.nmd.2014.09.010

M3 - Article

VL - 25

SP - 43

EP - 54

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 1

ER -